• Data
    • Overview
    • Clinical notes
    • Images
    • Mother-child
    • Oncology
    • Regulatory grade
    • Truveta Language Model
    • Truveta Studio
  • Genomics
  • Solutions
    • Life science
    • Public health
    • Healthcare
  • Research
  • Resources
  • About
    • Blog
    • Members
    • Leadership
    • Events & webinars
    • Newsroom
    • Careers
Get started
Sign in
Thin ice and slippery snow: Winter injury trends

Thin ice and slippery snow: Winter injury trends

by Truveta Research | Feb 7, 2024 | Research, Research Insights

We found 13.1 emergency department visits for falls on snow or ice per 10,000 emergency department visits during wintery months; with 3x higher rates happening in states with freezing temperatures during the winters compared to states with milder winters. Wrist...
Understanding the potential relationship between mental health and cannabis use

Understanding the potential relationship between mental health and cannabis use

by Truveta Research | Jan 11, 2024 | Research, Research Insights

There is a complex relationship between cannabis use and mental health. We studied recent time trends of the rate of cannabis-induced disorder emergency department visits and cannabis-involved emergency department visits (both defined below). Between 2019 and 2020, we...
First real-world comparative effectiveness study finds tirzepatide (Mounjaro) up to three times more effective than semaglutide (Ozempic) for weight loss

First real-world comparative effectiveness study finds tirzepatide (Mounjaro) up to three times more effective than semaglutide (Ozempic) for weight loss

by Truveta Research | Nov 27, 2023 | Research, Research Insights

In the first comparative effectiveness study of tirzepatide (Mounjaro) and semaglutide (Ozempic) for weight loss using real-world data, Truveta Research found that patients with overweight or obesity taking tirzepatide were three times more likely to achieve 15%...
Real-world prescribing of long-acting injectable cabotegravir for treatment of HIV in the United States

Real-world prescribing of long-acting injectable cabotegravir for treatment of HIV in the United States

by Truveta Research | Nov 10, 2023 | Research, Research Insights

Adequate treatments are a crucial piece in the fight against the spread of HIV, because they can make HIV viral load undetectable in the blood and thus untransmittable. Approved by the US Food and Drug Administration (FDA) in January 2021, one of the newest treatments...
Real-world trends in APOE genetic testing associated with lecanemab

Real-world trends in APOE genetic testing associated with lecanemab

by Truveta Research | Nov 10, 2023 | Research, Research Insights

Lecanemab received accelerated FDA approval in January 2023 and full FDA approval in July 2023. A potential side effect of the drug is brain swelling and/or small hemorrhages and is most common for people with the APOE ε4 genetic variant, therefore rates of APOE e4...
Autoimmune disease treatments: How marital status and sex impact medication adherence

Autoimmune disease treatments: How marital status and sex impact medication adherence

by Truveta Research | Nov 2, 2023 | Research, Research Insights

Adalimumab (Humira) and etanercept (Enbrel) are high-cost specialty medications used to treat a variety of autoimmune diseases. Medication adherence is often influenced by social drivers of health, so we aimed to measure adherence using the proportion of days covered...
« Older Entries
Next Entries »

Share this


Recent posts

  • New study finds GLP-1 RA medications may significantly reduce risk of alcohol-related hospitalization
  • Understanding the impact of the COVID-19 pandemic on childhood MMR vaccination patterns
  • Shifting trends in TKA fixation: Real-world evidence on the changing landscape of cemented vs uncemented TKA

Follow Truveta


Sign up for our newsletter

Ready to accelerate your research with representative, complete, and timely real-world data?

Truveta Data

Truveta Genome Project

Solutions

Research

Resources

Blog

Newsroom

Careers

Privacy notice

Contact us

© Truveta 2025

Our website uses cookies to ensure you have the best experience.AcceptPrivacy notice